Drosophila synapse formation: Regulation by transmembrane protein with leu-rich repeats, capricious

Science

Volumn 280, Issue 5372, 1998, Pages 2118-2121

  Shishido, Emiko ^a   Takeichi, Masatoshi ^b   Nose, Akinao ^a,c  

^a NATIONAL INSTITUTE FOR BASIC BIOLOGY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN;

AMINO ACID SEQUENCE; DROSOPHILA; GENE EXPRESSION REGULATION; GROWTH CONE; MOTONEURON; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNAPSE; TARGET CELL;

AMINO ACID SEQUENCE; ANIMALS; CLONING, MOLECULAR; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; GENE EXPRESSION; INSECT PROTEINS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MOTOR NEURONS; MUSCLES; MUTATION; NEUROMUSCULAR JUNCTION; PHENOTYPE; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 0032568882     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.280.5372.2118     Document Type: Review

References (53)

1. P. Garrity and S. L. Zipursky, Cell 83, 177 (1995); M. Tessier-Lavigne and C. S. Goodman, Science 274, 1123 (1996).
2. P. Garrity and S. L. Zipursky, Cell 83, 177 (1995); M. Tessier-Lavigne and C. S. Goodman, Science 274, 1123 (1996).
3. M. Bate and K. Broadie, Neuron 15, 513 (1995); H. Keshishian, K. Broadie, A. Chiba, H. Keshishian, Annu. Rev. Neurosci. 19, 545 (1996).
4. M. Bate and K. Broadie, Neuron 15, 513 (1995); H. Keshishian, K. Broadie, A. Chiba, H. Keshishian, Annu. Rev. Neurosci. 19, 545 (1996).
5. M. E. Halpern, A. Chiba, J. Johansen, H. Keshishian, J. Neurosci. 11, 3227 (1991); H. Sink and P. Whitington, Development 112, 307 (1991).
6. M. E. Halpern, A. Chiba, J. Johansen, H. Keshishian, J. Neurosci. 11, 3227 (1991); H. Sink and P. Whitington, Development 112, 307 (1991).
7. D. Van Vactor, H. Sink, D. Fambrough, R. Tsoo, C. S. Goodman, Cell 73, 1137 (1993).
8. M. Yoshihara, M. B. Rheuben, Y. Kidokoro, J. Neurosci. 17, 8408 (1997).
9. A. Nose, V. B. Mahajan, C. S. Goodman, Cell 70, 553 (1992).
10. The enhancer trap line E2-3-27 was isolated by V. Hartenstein and Y. N. Jan [Roux's Arch. Dev. Biol. 201, 194 (1992)].
11. aCC, RP2, and the most medial U innervate dorsal muscles 1, 2, and 10, respectively. RP5 innervates ventral muscle 12 (H. Sink and P. M. Whitington, J. Neurobiol. 22, 298 (1991); M. Landgraf, T. Bossing, G. M. Technau, M. Bate, J. Neurosci. 17, 9642 (1997)].
12. aCC, RP2, and the most medial U innervate dorsal muscles 1, 2, and 10, respectively. RP5 innervates ventral muscle 12 (H. Sink and P. M. Whitington, J. Neurobiol. 22, 298 (1991); M. Landgraf, T. Bossing, G. M. Technau, M. Bate, J. Neurosci. 17, 9642 (1997)].
13. Isolation of caps genomic and cDNA clones was according to standard methods.
14. B. Kobe and J. Deisenhofer, Trends Biochem. Sci. 19, 415 (1994).
15. B. Z. Chang et al., Dev. Biol. 160, 315 (1993).
16. D. E. Krantz and S. L. Zipursky, EMBO J. 9, 1969 (1990); F. J. Keith and N. J. Gay, ibid., p. 4299.
17. D. E. Krantz and S. L. Zipursky, EMBO J. 9, 1969 (1990); F. J. Keith and N. J. Gay, ibid., p. 4299.
18. The COOH-terminal peptide sequence AAGGYPY-IAGNSRMIPVTEL (see caption to Fig. 2 for amino acid abbreviations) of CAPS was used to immunize rabbits. The specificity of the antiserum was confirmed by its failure to stain caps mutant embryos and larvae.
19. We cannot detect CAPS protein expression on the surface of muscles before the formation of synapses. Like Fasciclin II, CAPS may shift from diffuse surface distribution to concentration at neuromuscular junctions [K. Zito, R. D. Fetter, C. S. Goodman, E. Y. Isacoff, Neuron 19, 1007 (1997)].
20. E. Shishido et al., data not shown.
21. 124.2, which showed the lowest viability and contained the largest deletions, were used in this study and gave similar results.
22. 65.2/Df(3L)Ly individuals survive to adulthood.
23. Monoclonal antibody 1D4 (antibody to Fasciclin II) (4), 2D5 (antibody to Fasciclin III) [N. H. Patel, P. M. Snow, C. S. Goodman, Cell 48, 975 (1987)], mAb 22C10 [S. C. Fujita, S. L. Zipursky, S. Benzer, A. Ferrus, S. L. Shotwell, Proc. Natl. Acad. Sci. U.S.A. 79, 7929 (1982)], and the ftz-tau-lacZ transgene [C. A. Callahan and J. B. Thomas, ibid. 91, 5972 (1994)] were used to evaluate axon architectures in the CNS and in the periphery. Muscle morphology was examined by Nomarsky optics.
24. Monoclonal antibody 1D4 (antibody to Fasciclin II) (4), 2D5 (antibody to Fasciclin III) [N. H. Patel, P. M. Snow, C. S. Goodman, Cell 48, 975 (1987)], mAb 22C10 [S. C. Fujita, S. L. Zipursky, S. Benzer, A. Ferrus, S. L. Shotwell, Proc. Natl. Acad. Sci. U.S.A. 79, 7929 (1982)], and the ftz-tau-lacZ transgene [C. A. Callahan and J. B. Thomas, ibid. 91, 5972 (1994)] were used to evaluate axon architectures in the CNS and in the periphery. Muscle morphology was examined by Nomarsky optics.
25. Monoclonal antibody 1D4 (antibody to Fasciclin II) (4), 2D5 (antibody to Fasciclin III) [N. H. Patel, P. M. Snow, C. S. Goodman, Cell 48, 975 (1987)], mAb 22C10 [S. C. Fujita, S. L. Zipursky, S. Benzer, A. Ferrus, S. L. Shotwell, Proc. Natl. Acad. Sci. U.S.A. 79, 7929 (1982)], and the ftz-tau-lacZ transgene [C. A. Callahan and J. B. Thomas, ibid. 91, 5972 (1994)] were used to evaluate axon architectures in the CNS and in the periphery. Muscle morphology was examined by Nomarsky optics.
26. No obvious abnormalities were seen in the nerve terminals of other muscles.
27. Neuromuscular terminals were visualized with mAb 1D4 (see 18).
28. 65.2/Df(3L)Ly third-instar larvae, 26.1% (n = 283) of the muscle 12 terminals contained abnormal arborization on muscle 13. In contrast, only 1.9% (n = 53) showed the abnormalities in control (+/Df(3L)Ly) individuals.
29. 65.2/ Df(3L)Ly, at frequencies of 71, 15, and 15%, respectively (n = 34).
30. Ectopic expression of caps was induced by GAL4-UAS system [A. H. Brand and N. Perrimon, Development 118, 401 (1993)]. Two independent transformant lines, UAS-caps-la (on the first chromosome) and UAS-caps-lb (on the third chromosome), were used and gave similar results. G14-GAL4 drives expression in all body-wall muscles from midstage 12 (D. Lin and C. S. Goodman, unpublished results; kindly provided by C. S. Goodman).
31. Ectopic expression of caps was induced by GAL4-UAS system [A. H. Brand and N. Perrimon, Development 118, 401 (1993)]. Two independent transformant lines, UAS-caps-la (on the first chromosome) and UAS-caps-lb (on the third chromosome), were used and gave similar results. G14-GAL4 drives expression in all body-wall muscles from midstage 12 (D. Lin and C. S. Goodman, unpublished results; kindly provided by C. S. Goodman).
32. Ectopic and increased expression of caps in all muscles by G14-GAL4 did not affect muscle development and adhesion (34).
33. In 72% of the hemisegments of G14-GAL4/+; UAS-caps-lb/+ third-instar larvae (n = 149), the muscle 12 terminal contained one or more collaterals that extended to muscle 13. In 25% of the hemisegments, the nerve branch extended further, to either muscle 5, 6, 8, or 30. However, these aberrations were observed in only 2% of the hemisegments of control larvae (UAS-caps-lb/+, n = 53). No obvious neuromuscular defects were seen in other regions of the body wall.
34. 65.2/Df(3L)Ly larvae contained 3.9 ± 1.3 (n = 12) boutons, whereas those in G14-GAL4/+; UAS-caps-lb/+ contained 15.7 ± 1.7 (n = 14) boutons.
35. M. Gorczyca, C. Augart, V. Budnik, J. Neurosci. 13, 3692 (1993).
36. In G14-GAL4/+; UAS-caps-lb/+ larvae, 31% (n = 91) of muscle 13 contained ectopic type III endings. Type III boutons were observed only in muscles 12 and 13, excluding the possibility that caps induces type III morphology. Ectopic synapses with type lb and type II are found in ∼40% and 20% of muscle 13, respectively. More than one type of bouton is found in some cases.
37. Ectopic endings on muscle 13 were observed in 5 of 11 segments in G14-GAL4/+; UAS-caps-lb/+ first-instar larvae.
38. 82-GAL4 drives expression from first-instar larval stage [G. W. Davis, C. M. Schuster, C. S. Goodman, Neuron 19, 561 (1997); G. W. Davis, C. S. Goodman, Nature 392, 82 (1998)].
39. 82-GAL4 drives expression from first-instar larval stage [G. W. Davis, C. M. Schuster, C. S. Goodman, Neuron 19, 561 (1997); G. W. Davis, C. S. Goodman, Nature 392, 82 (1998)].
40. This was further supported by the observation that overexpression of caps in muscle 13 but not in 12 by H94-GAL4 (30) can induce the formation of the ectopic synapses by muscle 12 motorneurons (E. Shishido et al., data not shown).
41. ftz-tau-lacZ transgene (18) was used to specifically visualize muscle 12 motorneurons in the embryos.
42. This contrasts with the phenotype caused by ectopic expression of fasciclin II on muscle 13, where many muscle 12 motor axons establish their synapses on muscle 13 before reaching muscle 12 (30). Even when caps overexpression has been induced in muscle 13 but not in 12 by H94-GAL4 (31), most muscle 12 motorneurons initially contact muscle 12.
43. A. Nose, T. Umeda, M. Takeichi, Development 124, 1433 (1997); S. Raghavan and R. A. H. White, Neuron 18, 873 (1997).
44. A. Nose, T. Umeda, M. Takeichi, Development 124, 1433 (1997); S. Raghavan and R. A. H. White, Neuron 18, 873 (1997).
45. A. Chiba, P. Snow, H. Keshishian, Y. Hotta, Nature 347, 166 (1995); H. Kose, D. Rose, X. Zhu, A. Chiba, Development 124, 4143 (1997).
46. A. Chiba, P. Snow, H. Keshishian, Y. Hotta, Nature 347, 166 (1995); H. Kose, D. Rose, X. Zhu, A. Chiba, Development 124, 4143 (1997).
47. This is consistent with the lack of increased muscle-muscle adhesion when caps is overexpressed (24). Expression of caps in S2 cells was conducted as described (6).
48. E. Shishido et al., data not shown.
49. D. J. Matthes, H. Sink, A. L. Kelodkin, C. S. Goodman, Cell 81, 631 (1995); K. J. Mitchell et al., Neuron 17, 203 (1996); D. Rose et al., Development 124, 1561 (1997).
50. D. J. Matthes, H. Sink, A. L. Kelodkin, C. S. Goodman, Cell 81, 631 (1995); K. J. Mitchell et al., Neuron 17, 203 (1996); D. Rose et al., Development 124, 1561 (1997).
51. D. J. Matthes, H. Sink, A. L. Kelodkin, C. S. Goodman, Cell 81, 631 (1995); K. J. Mitchell et al., Neuron 17, 203 (1996); D. Rose et al., Development 124, 1561 (1997).
52. A rabbit antiserum (GC1) that specifically stains type III endings was fortuitously obtained in our laboratory.
53. We thank V. Hartenstein and Y. N. Jan for making their collection of enhancer trap lines available. We also thank D. Lin and C. S. Goodman for GAL4 lines, Y. Shimoda and M. Kokubo for technical assistance, A. Chiba and M. Yoshihara for technical advice, and A. Chiba and S. Ritzenthaler for comments on the manuscript. Supported by research grants to A.N. and M.T. from the Ministry for Education, Science and Culture of Japan.